The Food and Drug Administration (FDA), the U.S. regulator of public health, said the United States does not approve its antibody drug Sotrovimab, branded as Xevudy. LexoSmithKline (GSK) of England and the Vermillion Company. US biotechnology (Vir) to treat COVID-19 in the US anymore After data showed that sotrovimab was ineffective once morest BA.2 subspecies of the Omicron virus. which spread faster than previous species Also at present It is the main species that spreads in the United States. It accounts for three-quarters of all new cases in the United States.
The order is effective in revoking the original order last month, which allowed the FDA to use sotrovimab. for the treatment of COVID-19 patients in most of the Northeastern United States
GSK and Vir confirmed their research that sotrovimab can stimulate antibodies or immune responses high enough to protect once morest BA.2. Including researchers from Columbia University disagree.
Company Vir, listed on the New York Stock Exchange. Sent a notice to the US Securities Exchange Commission that both GSK and Vir are in the process of preparing additional information to support their research. Increasing the dose of sotrovimab might be more effective in treating patients suffering from BA.2 virus, and the results will be presented to public health regulators around the world. and reiterating the company’s research results last month The drug reduced the risk of hospitalization and death by 79 percent.
Medicines and Healthcare Products Regulatory Agency The UK’s MHRA has approved the use of sotrovimab. for use for COVID-19 patients with mild to moderate symptoms and those at high risk of developing severe illness, with the goal of halting the incidence of severe illness in those affected by COVID-19. It is useful for people with weakened immune systems. The MHRA recommends taking the drug as soon as possible or within 5 days of onset of illness.
#USA
#Cancellation of sotrovimab
#COVID19